Novo Nordisk Investing $73M in Clayton, North Carolina, Facility
10/04/2010
"The investment to expand our Clayton facility is another example of our commitment to improving diabetes treatment options in the U.S. by ensuring patients have access to the latest advances in treatment," said Jerzy Gruhn, president of Novo Nordisk Inc. "Insulin delivery devices give people with diabetes a convenient way to manage their health and engage in a productive lifestyle. As patients in the U.S. continue to move from administering insulin with a conventional vial and syringe to using a pen device, Novo Nordisk will be prepared to meet growing market demand."
The facility produces Novo Nordisk products including the Levemir FlexPen. The expansion will add two final assembly lines, two packing lines, along with refurbishing the building.
Cost and productivity factors, including state and local incentives, helped Novo Nordisk choose Clayton. The company has been approved for Job Development Investment Grant funds, as well as a $400,000 One North Carolina Fund grant.
Project Announcements
Momentous Expands Summit County, Utah, Operations
12/21/2025
Stryker Expands Salt Lake County, Utah, Operations
12/21/2025
Portal Space Systems Expands Bothell, Washington, Operations
12/21/2025
TerraForge Biocarbon Solutions Plans Magnolia, Mississippi, Operations
12/20/2025
Coastal Ready Mix Plans Conway, South Carolina, Production Operations
12/20/2025
PRET Advanced Materials Expands Johnsonville, South Carolina, Manufacturing Operations
12/19/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025